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Congenital stationary night blindness (CSNB) is a clinically and genetically heterogeneous retinal disorder. Two forms can be distin-
guished clinically: complete CSNB (cCSNB) and incomplete CSNB. Individuals with cCSNB have visual impairment under low-light
conditions and show a characteristic electroretinogram (ERG). The b-wave amplitude is severely reduced in the dark-adapted state of
the ERG, representing abnormal function of ON bipolar cells. Furthermore, individuals with cCSNB can show other ocular features
such as nystagmus, myopia, and strabismus and can have reduced visual acuity and abnormalities of the cone ERG waveform. The
mode of inheritance of this form can be X-linked or autosomal recessive, and the dysfunction of four genes (NYX, GRM6, TRPM1,
and GPR179) has been described so far. Whole-exome sequencing in one simplex cCSNB case lacking mutations in the known genes
led to the identification of a missense mutation (c.983G>A [p.Cys328Tyr]) and a nonsense mutation (c.1318C>T [p.Arg440*]) in
LRIT3, encoding leucine-rich-repeat (LRR), immunoglobulin-like, and transmembrane-domain 3 (LRIT3). Subsequent Sanger
sequencing of 89 individuals with CSNB identified another cCSNB case harboring a nonsense mutation (c.1151C>G [p.Ser384*]) and
a deletion predicted to lead to a premature stop codon (c.1538_1539del [p.Ser513Cysfs*59]) in the same gene. Human LRIT3 antibody
staining revealed in the outer plexiform layer of the human retina a punctate-labeling pattern resembling the dendritic tips of bipolar
cells; similar patterns have been observed for other proteins implicated in cCSNB. The exact role of this LRR protein in cCSNB remains to
be elucidated.Congenital stationary night blindness (CSNB) is a clinically
and genetically heterogeneous group of retinal disorders
caused by mutations in genes implicated in the photo-
transduction cascade or in retinal signaling from photore-
ceptors to adjacent bipolar cells.1 Most of the individuals
affected by CSNB show a characteristic electroretinogram
(ERG) in which the b-wave amplitude is smaller than the
a-wave amplitude in the dark-adapted bright-flash condi-
tion.2 This electronegative waveform can be divided in
two subtypes, incomplete CSNB (icCSNB) (CSNB2A [MIM
300071] and CSNB2B [MIM 610427]) and complete
CSNB (cCSNB) (CSNB1A [MIM 310500], CSNB1B [MIM
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wave and substantially reduced cone responses, indicative
of both ON and OFF bipolar cell dysfunction. icCSNB has
been associated with mutations in CACNA1F (MIM
300110), CABP4 (MIM 608965), and CACNA2D4 (MIM
608171), genes coding for proteins important for the
continuous glutamate release at the photoreceptor
synapse.1 cCSNB is characterized by a drastically reduced
rod-b-wave response due to ON bipolar cell dysfunction,
as well as specific cone ERG waveforms.4 cCSNB has been
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Figure 1. LRIT3 Mutations and the Associated Electroretinographic Phenotype
(A) Family A (left) and family B (right), each with an affected individual who is a compound heterozygote for mutations in LRIT3, and
cosegregation analysis in available family members. The cCSNB-19018-affected index individual (II.1 of family A) used for whole-exome
next-generation sequencing is marked with a red arrow. The mother of I.2 of family A is deceased, which is highlighted by a crossed line.
Females and males are depicted by circles and squares, respectively. Filled and unfilled symbols indicate affected and unaffected status,
respectively. ERGs of a normal (‘‘unaffected’’) subject are compared with those of individuals II:1 from family A and II:1 from family B.
Normal ERGs have a rod-driven waveform, a mixed (combined) rod and cone response elicited by a bright flash of light, and two cone-
driven responses at different frequencies of stimulation (1 and 29 Hz). The ERGs from affected individuals II:1 from family A and II:1
from family B are typical of cCSNB and differ from a normal ERG as follows: there is a mixed response with a preserved negative compo-
nent of the waveform (a-wave [from photoreceptors]) but a reduced positive component (b-wave [from postreceptoral retinal activity]),
a cone-driven 1 Hz response with an unusual waveform, a cone-driven 29 Hz flicker ERG with a typical broadened trough and a mildly
delayed implicit time, and no detectable rod-driven waveform.
(B) LRIT3 (RefSeq NM_198506.3) structure containing four coding exons. Different mutations identified in persons with cCSNB are
depicted. Filled and unfilled boxes represent coding regions and UTRs of LRIT3, respectively. The start codon is indicated by an arrow.
(C) The translated amino acid sequence of LRIT3 (RefSeq NP_940908.3), predicted domains, and the different LRIT3 alterations of two
persons with cCSNB are indicated. The exact start and end of the domains vary depending on the different prediction programs used.bipolar cells. To date, more than 300 mutations have been
identified in the genes underlying icCSNB and cCSNB.5–24
Mutations in many genes associated with CSNB have been
identified through a candidate gene approach comparing
the human phenotype to similar phenotypes observed in
knockout or naturally occurring animal models,10–16,25
but techniques using massively parallel sequencing of all
human exons have recently been successful in identifying
mutations in genes underlying heterogeneous diseases,
including Leber congenital amaurosis and, more recently,
CSNB.18,26,27 Thus, to rapidly identify the gene defect of68 The American Journal of Human Genetics 92, 67–75, January 10, 2another autosomal-recessive-cCSNB-affected family
(family A, Figure 1A), previously excluded for known
cCSNB-associated gene defects, we sequenced the index
nonconsanguineous affected female after whole-exome
enrichment (IntegraGen, Evry, France). Research proce-
dures were conducted in accordance with institutional
guidelines and the Declaration of Helsinki; institutional-
review-board approvals were obtained from the partici-
pating universities and the national Ministries of Health
of each participating center. Prior to genetic testing,
informed consent was obtained from all CSNB-affected013
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The Amindividuals and their family members. Ophthalmic exam-
inations were performed on all subjects: a full-field ERG
incorporated the International Society for Clinical Electro-
physiology of Vision standards and methodology previ-
ously described.28–30 Exons of DNA samples were captured
and investigated as shown before with in-solution enrich-
ment methodology (SureSelect Human All Exon Kits
version 3, Agilent, Massy, France) and next-generation
sequencing (NGS) (Illumina HISEQ, Illumina, San Diego,
CA, USA). Image analysis and base calling were performed
with Real Time Analysis software (Illumina).18 Genetic-
variation annotations were performed by an in-house
pipeline (IntegraGen), and results were provided per
sample or family in tabulated text files. After very stringent
criteria were used for excluding variants observed in
dbSNP 132, HapMap, 1000 Genomes Project, and internal
(IntegraGen) variant-detection databases, the results were
further filtered so that only compound heterozygous or
homozygous variants in coding regions remained. This al-
lowed us to reduce the number of variants from 4,267 to
0 indels and from 50,807 SNPs to 21 homozygous variants
in 13 genes and 30 compound heterozygous variants in
10 genes. To determine the most likely disease-causing
gene defect for this cCSNB-affected family, we investigated
missense changes with bioinformatic tools to predict the
pathogenicity of the mutations and the conservation of
affected amino acid residues (PolyPhen-2,31 SIFT,32
KD4v,33 and the USCS Human Genome Browser). Those
genes harboring the selected variants were assessed for
eye and retinal expression with the use of the UniGene
database, the retinal gene-expression profile database
provided by Siegert et al.,34 and the in-house rd1 mouse
expression database (courtesy of Thierry Leveillard). On
the basis of these criteria, the only selected variants were
compound heterozygous mutations (c.983G>A
[p.Cys328Tyr] and c.1318C>T [p.Arg440*]) in exon 4 of
LRIT3 (RefSeq accession number NM_198506.3), which
encodes leucine-rich-repeat (LRR), immunoglobulin-like,
and transmembrane-domain 3 (LRIT3) (Figures 1A–1C;
family A). For the c.983G>A variant, the G and A were
found 463 and 533, respectively, and for c.1318C>T,
the C and T were present 703 and 543, respectively, indi-
cating that both variants were present heterozygously.
Both variants were absent in more than 340 control chro-
mosomes, and only c.983G>A (p.Cys328Tyr) was found at
a very low frequency (1 out of 10,757 alleles, indicating
that only one person was heterozygous for this substitu-
tion) in the National Heart, Lung, and Blood Institute
(NHLBI) Exome Sequencing Project Exome Variant Server
(EVS, 15.06.2012). The cystein at amino acid position 328
is highly conserved; only alpaca show a different amino
acid residue (Phe) (USCS Human Genome Browser
15.06.2012) (Table 1). PolyPhen-2, SIFT, and KD4v pre-
dicted this variant to be probably damaging (Table 1).
The second mutation, c.1318C>T (p.Arg440*), was
absent in all publically available databases, including the
EVS. Cosegregation analysis revealed that the unaffectederican Journal of Human Genetics 92, 67–75, January 10, 2013 69
father and brother were heterozygous for the p.Cys328Tyr
substitution. Subsequent Sanger sequencing of seven frag-
ments covering the four exons and flanking intronic
regions of LRIT3 (RefSeq NM_198506.3) (detailed condi-
tions will be communicated on request) in 89 individuals
(with cCSNB and unclassified CSNB) of various ethnic
origins and from different clinical centers in Europe, the
United States, Canada, Israel, and India (CSNB study
group) detected one additional cCSNB-affected person,
who carried compound heterozygous disease-causing
mutations (c.1151C>G [p.Ser384*] and c.1538_1539del
[p.Ser513Cysfs*59]) in exon 4 (Figures 1A–1C; family B).
Both variants cosegregated with the phenotype, were
absent in more than 370 control chromosomes, and
were not described in the current EVS database
(Figure 1A, family B). The frequencies of LRIT3 polymor-
phisms found in our individuals with CSNB are provided
in Table S1, available online. On the basis of all of the
above evidence, we conclude that mutations in LRIT3
lead to cCSNB.
In family A, used for the whole-exome NGS approach
(Figure 1A, family A), the index case (II.1) had visual blur-
ring and night-vision disturbances from childhood. When
she was 4 years old, spectacles for myopia were prescribed
and strabismus surgery was performed in the right eye. A
diagnosis was not specifically made, but the individual
recalls being told that she had a progressive blinding
disease with high myopia. Laser treatment of retinal tears
occurred when she was 25 years old. When she was 45
years of age, an ERG was taken for the first time
(Figure 1A, family A). The ERG features were those of
cCSNB: undetectable responses to a dim flash under dark-
adapted conditions (rod, Figure 1A, family A), a negative
waveform in the mixed rod-cone response in the dark-
adapted state, and an unusual square-shape appearance
of the a-wave in the cone ERG1,14,18 (29 Hz, Figure 1A,
family A). In the detectable ERGs, amplitudes were abnor-
mally reduced, a result that might be associated with high
myopia.35 Visual acuities were 20/80 (26.00 D sphere) in
the right eye and 20/30 (27.00 D sphere) in the left eye.
Eye pressures were normal, and the fundus appearance
was that of myopia (1 Hz, Figure 1A). Other than under-
going eye-muscle and laser surgery (see above), the index
case had arthroscopic knee surgery in her 40s. In family
B, the affected person was diagnosed with high myopia
at the age of 2 years. Prominent night blindness was also
noticed at that age, and later on, visual acuity was found
to be decreased. She had no photoaversion or loss in the
peripheral visual field. At the time of presentation, 9 years
of age, visual acuities were 20/40 (7.00 D sphere) in the
right eye and 20/50 (8.00 D sphere) in the left eye. Lenses
were transparent, and the fundus appearance was that of
myopia with a tilted optic disc. Fundus autofluorescence
was normal. An optical-coherence-tomography-3 scan of
the maculae disclosed a normal photoreceptor layer. Light
sensitivity was foundmoderately decreased over the whole
visual field. She had an electronegative ERG mixed rod-70 The American Journal of Human Genetics 92, 67–75, January 10, 2cone response in the dark-adapted state (Figure 1A, family
B). In addition, there were moderately reduced cone 30 Hz
flicker responses, an atypical waveform in the light-
adapted state (1 Hz, Figure 1A, family B), and no ERG
responses to dim stimuli in the dark-adapted state (rod,
Figure 1A, family B); all of these findings are compatible
with the diagnosis of cCSNB (Figure 1A, family B).
To date, only little information is available on the
expression, localization, and function of LRIT3. It maps
to chromosomal region 4q25 and contains four exons,
the first of which was only recently identified and codes
for a protein with 679 amino acids.36 An available ex-
pressed-sequence-tag (EST) profile (from the UniGene
EST Profile Viewer) indicates that the gene is expressed in
the brain and the eye. Real-time-PCR experiments and
subsequent Sanger sequencing of amplified real-time-PCR
products confirmed the expression of LRIT3 in the human
retina (commercially available cDNA fromClontech, Saint-
Germain-en-Laye, France) by giving a signal of DCT ¼ 6.33
(CT LRIT3 ¼ 24.96) in relation to b-actin (ACTB [MIM
102630]) (CT ACTB ¼ 18.63) (primers Table S2).
To immunolocalize the exact location of LRIT3 in the
retina, we used a validated human LRIT3 antibody (Figures
S1 and S2) in human retina from a cryosectioned eye and
performed immunostainings. LRIT3 localization could be
detected in the outer plexiform layer (OPL) (Figures 2A
and 2B, green). Immunofluorescence was analyzed with
a confocal microscope (FV1000 fluorescent, Olympus,
Hamburg, Germany). Colocalization studies with an anti-
body against a mouse Goa (Millipore, Molsheim, France),
a specific ON bipolar cell marker (Figures 2A and B, red),
demonstrated that human LRIT3 antibody reveals a charac-
teristic synaptic punctate labeling at the dendrites of depo-
larizing bipolar cells. Comparing this immunostaining
with the immunostaining from other molecules impli-
cated in cCSNB, we conclude that the dotted punctate
labeling (arrows) represents multiple rod bipolar cell
dendritic tips that invaginate a rod spherule and that the
innermost punctate labeling organized in rows (arrow-
heads) represents labeling of cone bipolar cell tips that
invaginate the foot of a cone pedicle (Figure 2B).37,38
Fainter green fluorescence signal was also detected in other
retinal layers and especially in the photoreceptor layers. In
these latter layers, a comparable faint signal was also de-
tected in human retina with only the use of secondary
antibodies, indicating that this signal is not specific to
LRIT3. Future studies on wild-type and knockout mice
retinas with a mouse LRIT3 antibody are warranted for
further validating whether LRIT3 is present in retinal layers
other than the OPL.
LRIT3 (RefSeq NP_940908.3) is predicted to belong to
the LRR protein family, which contains a signal peptide
(amino acids 1–19) and four LRR domains (amino acids
82–104, 106–128, 130–152, and 154–176), which are
flanked by cysteine-rich LLRNT (amino acids 20–61) and
LRRCT (amino acids 201–253) motifs. Furthermore,
an immunoglobulin-like (Ig-like) domain (amino acids013
Figure 3. Genes Underlying CSNB
Different forms of CSNB in humans are classified according to
their electroretinographic features, mode of inheritance, clinical
phenotype, and mutated genes. Affected individuals discussed
herein show a complete type of Schubert-Bornschein ERG.
Genes are indicated in italics and are underlined. Chromosomal
locations are given in parentheses. The following abbreviations
are used: cCSNB, complete CSNB; icCSNB, incomplete CSNB;
AR, autosomal recessive; and AD, autosomal dominant.
Figure 2. LRIT3 Immunohistochemistry in Human Retinal
Sections
(A) LRIT3 signal (green) in the OPL double labeled with an ON
bipolar cell marker against Goa (red) was detected in the human
retina by confocal microscopy. A strong signal with the human
LRIT3 antibody was detected in a punctate manner at presumable
dendritic tips of the ON bipolar cells (16 stacks of the confocal-
microscopy image were chosen). The following abbreviations are
used: PHR, photoreceptor layer; ONL, outer nuclear layer; OPL,
outer plexiform layer; INL, inner nuclear layer; and GCL, ganglion
cell layer.
(B) A 3.53 zoom of (A) focuses on LRIT3 staining at presumable
dendrites of the bipolar cells (three stacks of the confocal-micros-
copy image were chosen). The scale bar represents 20 mm.254–344), a fibronectin type III (FNIII) domain (amino
acids 484–574), and a transmembrane (TM) domain
(amino acids 583–633) were annotated (UniProtKB/Swiss-The AmProt and SMART). The C-terminal region is highly
conserved and might harbor a PDZ-binding motif. More
specifically, according to Tian et al.39 and to publicly avail-
able motif research programs (ELM: The Database of Eu-
karyotic Linear Motifs), the C-terminal amino acid residues
‘‘ESQV’’ and ‘‘RPEYYC,’’ respectively, are good candidates
to represent such PDZ-binding motifs (Figure 1C). In
addition, LRIT3 contains a serine-rich region (amino acids
373–433) and the two cysteine residues, Cys275 and
Cys328, predicted to form disulfide bonds (UniProtKB/
Swiss-Prot) (Figure 1C). Recent in vitro studies have sug-
gested that LRIT3 can regulate a fibroblast-growth-factor
receptor, FGFR1.36 Although FGFR1 is expressed in many
tissues, including the retina (UniGene EST Profile Viewer),
a role for FGFR1 in bipolar cells has not yet been re-
ported.40 The mutation spectrum described here affects
different LRIT3 domains, including the Cys328 residue,
which is predicted to form a disulfide bond in the Ig-like
domain. Disulfide bonds have been shown to be important
for folding and stability of some proteins and especially in
proteins secreted to the extracellular medium.41 The
p.Cys328Tyr substitution might thus lead to accumulation
of misfolded protein in the endoplasmic reticulum, as has
been illustrated for substitution p.Cys203Arg, which
affects a disulfide bond in the green opsin and leads to
anomalous trichromacy.42 Interestingly, cysteine substitu-
tions have also been described in the protein encoded by
NYX (RefSeq NM_022567.2), another gene associated
with cCSNB (Figure 3). We and others found that NYX
missense mutations c.143G>A and c.144C>G, respec-
tively, lead to substitutions p.Cys48Tyr (associated with
CSNB without myopia)6 and p.Cys48Trp (associated with
CSNB with isolated myopia),43 respectively. The Cys48
residue was predicted to be important for proteinerican Journal of Human Genetics 92, 67–75, January 10, 2013 71
stabilization via disulphide bridging. Because both substi-
tutions are predicted to probably destabilize the protein
structure, the phenotypic variability still needs to be eluci-
dated. However, it is striking that most of the individuals
with mutations in genes underlying the complete form
of CSNB show high myopia. It has been suggested that
altered cone signal resulting from mutations in genes
important for the ON pathway might participate in
myopia.43 Blurred images seen by the affected persons
might create an aberrant retinal signal before the local
eye can react to retinal blur and might therefore induce
myopia.44–47
The three other mutations represent two nonsense
mutations and a frameshift, which are located in the last
exon. Thus, it is likely that mutant mRNA products escape
nonsense-mediated decay. The p.Ser384* truncated
protein is predicted to lack the serine-rich, FNIII, and TM
domains and the PDZ-binding motifs; the p.Arg440*
altered protein is predicted to lack the FNIII and TM
domains and the PDZ-binding motifs; and the p.Ser513-
Cysfs*59 truncated protein is predicted to lack the TM
domain and the PDZ-binding motif. Given that all altered
proteins are predicted to lack the TM motif, they might
lead to a protein that cannot be targeted to the membrane
and that therefore cannot function at its predicted site.
Considering the different domains present in LRIT3, the
protein resembles most LRIT1 and LRIT2 of unknown
function, as well as SALM1, SALM2, and SALM3 of the
synaptic-cell-adhesion-molecule protein family. These
proteins contain LRRs; LLRNT and LRRCT motifs; Ig-like,
FNIII, and TM domains; and an intracellular C-terminal
PDZ-binding motif, which interacts within the SALM
protein family with PSD-95, an abundant postsynaptic
scaffolding protein.48,49 Compared to the SALM family,
in which proteins always have six LRRs, LRIT3 contains
only four. This protein family has been shown to be impor-
tant in synapse formation.More precisely, SALM1 has been
implicated in clustering NMDA receptors, and an altered
SALM1 lacking PSD-95 binding fails to cluster these recep-
tors. SALMS2 is targeted to and stabilized at excitatory
synapses via its interaction with PSD-95, where it recruits
NMDA and AMPA receptors to promote excitatory
synaptic maturation. SALM1, SALM2, and SALM3 form
homomeric and heteromeric complexes with each
other.49 In ON bipolar cells, TRPM1 represents the channel
that opens after light stimulation, leading to the ERG b-
wave, which is severely reduced in individuals with
cCSNB.14,50,51 We and others have recognized low-surface
TRPM1 localization in overexpressing mammalian cells.52
Studies by Pearring et al. showed that the presence of
NYX located in the dendritic tips of ON bipolar cells is
necessary for the dendritic-tip localization of TRPM1.38 A
mouse model lacking NYX led to the absence of
dendritic-tip labeling of TRPM1. The authors suggested
that NYX is localized to the ON bipolar cell dendritic
tips, subsequently interacts with TRPM1, and thereby
establishes the correct TRPM1 localization. They also72 The American Journal of Human Genetics 92, 67–75, January 10, 2mention that another ancillary protein would be needed
to interact with intracellular scaffolding complexes to
hold the TRPM1 channels to the bipolar cell synapse.
Given the fact that LRIT3 has a PDZ-binding motif, it
might be the missing molecule interacting with scaf-
folding proteins to bring TRPM1 to the surface of the
cell, and thereafter, NYX and LRIT3 hold the channel in
this form. Confirming this hypothesis will require in vivo
and in vitro studies.
Including in this study, mutations in five genes (NYX,
GRM6, TRPM1, GPR179, and LRIT3) have been implicated
in cCSNB (Figure 3).8–11,14–16,18,19,25 These genes code
for nyctalopin, metabotropic glutamate receptor 6, tran-
sient receptor potential cation melastatin 1, G-protein-
coupled receptor 179, and LRIT3, respectively. All localize
postsynaptically to the photoreceptors in the retina
in ON bipolar cells.19,37,38,53 Further functional studies
will eventually clarify the exact role of LRIT3 within the
ON bipolar cell pathway, which will also improve our
understanding of the overall visual signal transduction
through the retina.Supplemental Data
Supplemental Data include two figures and two tables and can be
found with this article online at http://www.cell.com/AJHG.Acknowledgments
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